News Archive

2021

November

Media Release / Nov 08, 2021

Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021

Read More
Media Release / Nov 04, 2021

Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)

Read More
Media Release / Nov 01, 2021

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Read More

October

Media Release / Oct 14, 2021

Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosis

Read More
Media Release / Oct 13, 2021

Novartis announces FDA and EMA filing acceptances of BEOVU® for patients with diabetic macular edema

Read More

September

Media Release / Sep 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Read More
2020

June

Media Release / Jun 11, 2020

U.S. FDA approves updated Novartis BEOVU® label, to include additional safety information
Media Release / Jun 16, 2020

Novartis ILARIS® (canakinumab) receives FDA approval for new indication to treat Adult-Onset Still’s Disease (AOSD)

Read More
Media Release / Jun 16, 2020

Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

Read More

Related Links